뒤로
Clarity Pharmaceuticals Ltd(CLRPF) 가격
CLRPF 주가 차트
CLRPF 수입
Clarity Pharmaceuticals Ltd
$2.3
2.22%
$0.04
종가: Jan 16, 16:00:00 GMT-5
$2.3
0%
$0
애프터마켓: Jan 16, 20:00:00 GMT-5
주요 통계
이전 종가
$2.25
시가
$2.3
일일 범위
$2.3 - $2.3
52주 범위
$0.842 - $3.6
거래량
--
평균 거래량
3.1K
EPS(TTM)
-0.13
배당수익률
--
시가총액
$855.6M
CLRPF란 무엇인가요?
Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. The company is headquartered in Eveleigh, New South Wales. The company went IPO on 2021-08-25. The firm is focused on developing targeted copper theranostics based on its SAR Technology Platform. The company is progressing clinical trials with its approximately three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. Its lead product, SAR-bisPSMA, is progressing through over three clinical trials: one theranostic trial (SECuRE) and two Phase III diagnostic trials (CLARIFY and AMPLIFY). SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2). SAR-bisPSMA is developed for diagnosing, staging, and treating prostate cancer that expresses prostate-specific membrane antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer.